Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOVACC maintenance therapy trial in BRCA wild-type recurrent ovarian cancer
NL-OMON59264Phase 2Active, not recruiting
- Sponsor
- Nordic Society of Gynaecological Oncology Clinical Trial Unit
- Start
- Dec 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of olaparib, durvalumab, UV1 and sargramostim in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by Nordic Society of Gynaecological Oncology Clinical Trial Unit. Primary endpoint: Progression-free survival. Started Dec 2024; status: active, not recruiting.
02
Drugs
olaparibdurvalumabUV1sargramostim
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON59264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59264.